| symbol |
GRTS |
|---|
| 会社名 | Gritstone Oncology Inc （グリットスト―ン・オンコロジ―） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Biotechnology: Biological Products (No Diagnostic Substances)
|
|---|
| 業種 |
医薬品
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Gritstone Oncology Inc. is an immuno-oncology company that develops tumor-specific cancer immunotherapies to fight multiple cancer types. The Company focuses to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop treatments for lung cancer. It provides Gritstone EDGE which is a tumor-specific neo-antigen (TSNA) prediction platform that predicts the presence of a patient’s TSNA on tumor cells. It also develops and manufactures a patient-specific therapeutic to direct a robust thymus (T) cell response to those TSNA predicted to be presented on the patient’s tumor. In its GRANITE-001 product candidate each of the viral prime and RNA boost immunizations contain a patient-specific set of predicted TSNA and the viral prime and RNA boost in its SLATE product candidate series contains a fixed TSNA cassette that is designed for the subset of patients with tumor neoantigens. グリットスト―ン・オンコロジ―は米国の新薬開発企業。AI技術を利用したがん治療のパイプラインを開発。各患者の腫瘍の個々の性質に焦点を当て、同社のAIプラットフォ―ムGritstone EDGEの予測能力を組み合わせることにより、複数のタイプのがんと闘う患者向けに個人化免疫療法を開発、提供する。本社所在地はカリフォルニア州エメリ―ビル。 Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.
|
|---|
| 本社所在地 | 5858 Horton Street Suite 210 Emeryville CA 94608 USA |
|---|
| 代表者氏名 | Andrew R. Allen アンドリュー・R・アレン |
|---|
| 代表者役職名 | President Chief Executive Officer Co-Founder Director |
|---|
| 電話番号 | +1 510-871-6100 |
|---|
| 設立年月日 | 42217 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2018年 |
|---|
| 従業員数 | 100人 |
|---|
| url | www.gritstoneoncology.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/grts |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -53.00400 |
|---|
| 終値（lastsale） | 11.88 |
|---|
| 時価総額（marketcap） | 0 |
|---|
| 時価総額 | 時価総額（百万ドル） 423.78200 |
|---|
| 売上高 | 売上高（百万ドル） 0.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 535.66500 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -55.66800 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Gritstone Oncology Inc revenues was not reported. Net loss increased 98% to $28.8M. Higher net loss reflects Research and development - Bala increase from $11.5M to $23.5M (expense) General and administrative - increase of 57% to $4.3M (expense) Stock-based Compensation in SGA increase from $111K to $578K (expense). |
|---|
GRTS - グリットスト―ン・オンコロジ― （Gritstone Oncology Inc.） グリットスト―ン・オンコロジ―